{"id":"89cd7835-de40-5174-8d05-1914a30477fc","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-irinotecan-cd26","predicate":"increases_in_recorded_comparison","statement":"Apigenin plus irinotecan increased CD26 expression in the reported HT-29 combination assay.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"309baaa2-4ce4-5e4a-af8e-b2891fc401cc","mechanism_event_label":"Apigenin plus irinotecan increased CD26 expression in the reported HT-29 combination assay.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"a8650e3d-e30f-5fcf-8811-2d4055819356","slug":"human-dpp4","display_name":"Human dipeptidyl peptidase 4 / DPP4 / CD26","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"309baaa2-4ce4-5e4a-af8e-b2891fc401cc","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-irinotecan-cd26-event","event_type":"experimental_observation","label":"Apigenin plus irinotecan increased CD26 expression in the reported HT-29 combination assay.","description":"### api-irinotecan-cd26\n\nApigenin plus irinotecan increased CD26 expression in the reported HT-29 combination assay.\nDo not translate this expression interaction into proven synergistic tumor killing or a clinical co-treatment recommendation.\nModel and exposure: Cell-surface CD26 endpoint; the paper also tested other topoisomerase drugs.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | 2022 | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin plus irinotecan","sequence_order":0,"notes":""},{"entity":{"id":"a8650e3d-e30f-5fcf-8811-2d4055819356","slug":"human-dpp4","display_name":"Human dipeptidyl peptidase 4 / DPP4 / CD26","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_condition","value_text":"Apigenin plus irinotecan","comparator":"Single-agent comparison reported by the study","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"experimental_condition","value_text":"co-administered","comparator":"Single-agent comparison reported by the study","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"irinotecan","display_name":"Irinotecan","entity_type_key":"drug"}},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin plus irinotecan\", \"comparator\": \"Single-agent comparison reported by the study\", \"endpoint\": \"Apigenin plus irinotecan increased CD26 expression in the reported HT-29 combination assay.\", \"effect_direction\": \"increase\", \"combination\": \"joint\", \"conditions\": [{\"entity_slug\": \"apigenin\", \"state\": \"Apigenin plus irinotecan\"}, {\"entity_slug\": \"irinotecan\", \"state\": \"co-administered\"}]}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Cell-surface CD26 endpoint; the paper also tested other topoisomerase drugs.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin plus irinotecan increased CD26 expression in the reported HT-29 combination assay.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-irinotecan-cd26; Do not translate this expression interaction into proven synergistic tumor killing or a clinical co-treatment recommendation.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"db0fdd05-beaf-54bc-98cd-0bbe1772c9c7","evidence_kind":"source_excerpt","locator":"Lines 740-746","start_line":740,"end_line":746,"excerpt":"### api-irinotecan-cd26\n\nApigenin plus irinotecan increased CD26 expression in the reported HT-29 combination assay.\nDo not translate this expression interaction into proven synergistic tumor killing or a clinical co-treatment recommendation.\nModel and exposure: Cell-surface CD26 endpoint; the paper also tested other topoisomerase drugs.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | 2022 | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Cell-surface CD26 endpoint; the paper also tested other topoisomerase drugs.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}